Notes: June 27, 2024 -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares. The reverse stock split will become effective at 12:01 A.M. Eastern Time, on July 1, 2024. The Company's common stock will continue to be traded on the NYSE American under the symbol “AZTR” and will begin trading on a split-adjusted basis when the market opens on July 1, 2024. The new CUSIP number for the Company’s common stock following the reverse stock split will be 05479L03.